Polyvinylpyrrolidone in hemodialysis membranes: Impact on platelet loss during hemodialysis
Hemodialysis International · 2021-10 · 25 (4) · 498-506
DOI: 10.1111/hdi.12939 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hemodialysis International, online erschienen am 04.06.2021. Verfasst von Adam M Zawada und 5 weiteren Autor:innen. Beteiligte Einrichtung: Global Research and Development, Product Engineering Center Dialyzers & Membranes, Product Development, Fresenius Medical Care Deutschland GmbH, Sank…. Hauptthemen laut MEDLINE: Povidone, Renal Dialysis. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 42 Literaturangaben.
Abstract (Originalsprache)
Introduction
Hydrophilic modification with polyvinylpyrrolidone (PVP) increases the biocompatibility profile of synthetic dialysis membranes. However, PVP may be eluted into the patient's blood, which has been discussed as a possible cause for adverse reactions rarely occurring with synthetic membranes. We investigated the content of PVP and its elution from the blood‐side surface from commercially available dialyzers, including the novel FX CorAL, with PVP‐enriched and α‐tocopherol‐stabilized membrane, and link the results to the level of platelet loss during dialysis as a maker of biocompatibility.
Methods
Six synthetic, PVP containing, dialyzers (FX CorAL, FX CorDiax [Fresenius Medical Care]; Polyflux, THERANOVA [Baxter]; ELISIO [Nipro]; xevonta [B. Braun]) were investigated in the present study. The content of PVP on blood‐side surface was determined with X‐ray photoelectron spectroscopy (XPS). The amount of elutable PVP was measured photometrically after 5 h recirculation. The level of platelet loss was evaluated in an ex vivo recirculation model with human blood.
Findings
Highest PVP content on the blood‐side surface was found for the polysulfone‐based FX CorAL (26.3%), while the polyethersulfone‐based THERANOVA (15.6%) had the lowest PVP content. Elution of PVP was highest for the autoclave steam‐sterilized THERANOVA (9.1 mg/1.6 m 2 dialyzer) and Polyflux (9.0 mg/1.6 m 2 dialyzer), while the lowest PVP elution was found for the INLINE steam sterilized FX CorAL and FX CorDiax (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Global Research and Development, Product Engineering Center Dialyzers & Membranes, Product Development, Fresenius Medical Care Deutschland GmbH, Sankt Wendel, Germany.
- Global Research and Development, Product Engineering Center Dialyzers & Membranes, Biosciences-Biotechnology, Fresenius Medical Care Deutschland GmbH, Sankt Wendel, Germany.
- Global Medical Office, Clinical and Epidemiological Research, Fresenius Medical Care Deutschland GmbH, Bad Homburg, Germany.
ORCID-Profile: Adam M Zawada
Zitieren
APA
Zawada, A. M., Melchior, P., Erlenkötter, A., Delinski, D., Stauss-Grabo, M., & Kennedy, J. P. (2021). Polyvinylpyrrolidone in hemodialysis membranes: Impact on platelet loss during hemodialysis. Hemodialysis International, 25(4), 498-506. https://doi.org/10.1111/hdi.12939
Vancouver
Zawada AM, Melchior P, Erlenkötter A, Delinski D, Stauss-Grabo M, Kennedy JP. Polyvinylpyrrolidone in hemodialysis membranes: Impact on platelet loss during hemodialysis. Hemodialysis International. 2021;25(4):498-506. doi:10.1111/hdi.12939
BibTeX
@article{Zawada2021,
author = {Zawada, Adam M and Melchior, Pascal and Erlenkötter, Ansgar and Delinski, Dirk and Stauss-Grabo, Manuela and Kennedy, James P},
title = {Polyvinylpyrrolidone in hemodialysis membranes: Impact on platelet loss during hemodialysis},
journal = {Hemodialysis International},
year = {2021},
volume = {25},
number = {4},
pages = {498--506},
doi = {10.1111/hdi.12939}
}
EUVIMED